ReviewRheumatic diseases clinics of North America2015
Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.
Review in Rheumatic diseases clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.Rheumatology (Oxford, England) · 2024Trial
- Towards a Better Prognosis in Patients with Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Recent Developments and Perspectives.Journal of clinical medicine · 2024Review
- Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.Rheumatology (Oxford, England) · 2023Article
- Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.Respiratory research · 2023Article
- Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis.The European respiratory journal · 2022Article
- Transferability of radiomic signatures from experimental to human interstitial lung disease.Frontiers in medicine · 2022Article
- Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening.Cureus · 2021Review
- Natural variability in the disease course of SSc-ILD: implications for treatment.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice.Frontiers in medicine · 2021Article
- Predictors of progression in systemic sclerosis patients with interstitial lung disease.The European respiratory journal · 2020Review
- [Treatment of systemic sclerosis-associated interstitial lung disease].Zeitschrift fur Rheumatologie · 2020Review
- Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.Journal of scleroderma and related disorders · 2020Article
- Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.Journal of clinical medicine · 2020Review
- Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020Article
- Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2019Review
- Interstitial lung disease associated with systemic sclerosis (SSc-ILD).Respiratory research · 2019Review
- Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.Open access rheumatology : research and reviews · 2019Article
- Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease.Clinical epidemiology · 2019Article
- Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.Reumatologia · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although scleroderma-associated interstitial lung disease (SSc-ILD) is a significant contributor to both morbidity and mortality, its pathogenesis is largely unclear. Pulmonary function tests and high-resolution computed tomographic scanning continue to be the most effective tools to screen for lung involvement and to monitor for disease progression. More research and better biomarkers are needed to identify patients most at risk for developing SSc-ILD as well as to recognize which of these patients will progress to more severe disease. Although immunosuppression remains the mainstay of treatment, antifibrotic agents may offer new avenues of treatment for patients with SSc-ILD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.